Tag Archives: carboplatin

A New Method to Treat Chemotherapy-Induced Neuropathic Pain

Posted on March 12, 2012 by wngai

If you are cancer patients and have to receive chemotherapy agents such as taxanes (paclitaxol- Taxol and docetaxel-Taxotere), vinca alkaloids (vinorelbine-Navelbine) and platinum compounds (cisplatin, carboplatin – Paraplatin and oxaliplatin – Eloxatin), it is likely that you might experience chemotherapy … Continue reading →

Posted in Anal Cancer, Bladder Cancer, Breast cancer, Cancer, Colorectal cancer, Endometrial Cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Glioblastma, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Renal Cancer, Small Cell Lung Cancer | Tagged , , , , , , , , , , , , , , , , | Comments Off on A New Method to Treat Chemotherapy-Induced Neuropathic Pain

Which is Best Chemotherapy Option for Advanced Bladder Cancer?

Posted on May 15, 2011 by wngai

Transitional cell or urothelial carcinoma is the most common type of bladder cancer, accounting for more than 90% all bladder cancers.  This type of cancer is sensitive to treatment with chemotherapeutic agents.   This type of cancer is usually treated with … Continue reading →

Posted in Bladder Cancer, Cancer | Tagged , , , , , , , , , , | Comments Off on Which is Best Chemotherapy Option for Advanced Bladder Cancer?

First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population

Posted on October 16, 2010 by wngai

First-line erlotinib (Tarceva) tripled the progression-free survival in advanced non–small cell lung carcinoma (NSCLC) patients who had endothelial growth factor receptor (EGFR)-activating mutation, according to the OPTIMAL study presented at the 35th European Society for Medical Oncology Congress. The study … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , , | Comments Off on First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population

Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations

Posted on July 25, 2010 by wngai

Gefitinib (Iressa) is more effective than first-line therapy in improving survival without disease in patients with advanced nonsmall-cell lung cancer (NSCLC) and epidermal growth-factor receptor (EGFR) mutations.  The current study was conducted in 230 patients from 43 centers in Japan, … Continue reading →

Posted in Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , | Comments Off on Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations

Avastin Boosts Progression-Free Survival in Ovarian Cancer Patients

Posted on June 26, 2010 by wngai

Adding bevacizumab (Avastin) to chemotherapy, followed by bevacizumab as maintenance therapy, can significantly prolong progression-free survival in women with advanced ovarian cancer.  The study consisted of 1873 women with newly diagnosed stage III (macroscopic residual disease) or stage IV ovarian, primary peritoneal, … Continue reading →

Posted in Cancer, Ovarian Cancer | Tagged , , , , , , | Comments Off on Avastin Boosts Progression-Free Survival in Ovarian Cancer Patients

Alternative Treatment Options for Late Stage Lung Cancer Patients

Posted on March 7, 2010 by wngai

Paclitaxel plus carboplatin(PC) is the current standard regimen for advanced or metastatic non-small-cell lung cancer (NSCLC) patients.  However, paclitaxel is associated with serious toxicity such as peripheral neuropathy. A tria,l published in October version of the Annals of Oncology, was … Continue reading →

Posted in Cancer, Lung Cancer | Tagged , , , , , , , , | Comments Off on Alternative Treatment Options for Late Stage Lung Cancer Patients